4D Molecular Therapeutics announced clinical pipeline progress, updates to near-term milestones and organizational updates. 4D-150 for Wet AMD: Phase 2 PRISM Clinical Trial. Randomized Dose Expansion arm (N=50) in advanced high treatment need patients: Initial interim 24 week landmark data to be presented at the Angiogenesis, Exudation, and Debeneration 2024 Conference on February 3, 2024 followed by a corporate webcast with details to be announced at a future date.

Population Extension arm (N45) in broad population (non-advanced, standard treatment-need): Enrollment update expected in first quarter 2024; Initial interim 24 week landmark data analysis expected in second quarter 2024; received both RMAT and PRIME in fourth quarter 2023, enabling increased collaboration between the FDA and EMA on regulatory approval planning, in addition to the opportunity for expedited product development; Update on Phase 3 trial plans expected in February 2024 along with the interim randomized Phase 2 PRISM trial data; 4D-150 for DME: Phase 2 SPECTRA Clinical Trial: Part 1 - Dose Confirmation Stage; Completed enrollment in fourth quarter 2023; Initial interim 24 week landmark Data expected in second quarter 2024; 4D-175 for Geographic Atrophy: IND filing expected in second quarter 2024; Phase 1 initiation expected in second quarter 2024.